Showing 2031-2040 of 2192 results for "".
- FDA Clears Trigeminal Nerve Stimulator Migraine Treatment for Use Without Prescriptionhttps://practicalneurology.com/news/fda-clears-trigeminal-nerve-stimulator-migraine-treatment-for-use-without-prescription/2469399/The Food and Drug Administration (FDA) has cleared the external trigeminal nerve stimulator (Cefaly Dual; Cefaly Technology, New York, NY ) for the acute and preventative migraine treatment in individuals age 18 years or more without a prescription. Initial purchase of the device
- Gene Therapy Improves ON Time for Individuals With Parkinson Disease in Phase 3 Trialhttps://practicalneurology.com/news/gene-therapy-improves-on-time-for-individuals-with-parkinson-disease-in-phase-3-trial/2469394/The 6-month follow-up data of a phase 2 study of a .4 x 107 TU dose of gene therapy (AXO-Lenti-PD; Axovant Gene Therapies, New York, NY) for Parkinson disease (PD) treatment showed the gene therapy improved ON time by more than 2-hours. The therapy is delivered to the putamin in a neurosurgi
- Soticlestat in Rare Epilepsies CDKL5 Deficiency and Dup15q Syndrome Phase 2 Clinical Trialshttps://practicalneurology.com/news/soticlestat-in-rare-epilepsies-cdkl5-deficiency-and-dup15q-syndrome-phase-2-clinical-trials/2469390/In the ARCADE (NCT03694275) and ENDYMION (NCT03635073) studies of soticlestat (OV935/TAK-935, Ovid Therapeutics, New York, NY) seizure frequency in individuals with CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) decreased. The combined data from ARCADE and ENDYMION studies
- Risdiplam Improves Motor Function in Infants with Type 1 SMAhttps://practicalneurology.com/news/risdiplam-improves-motor-function-in-infants-with-type-1-sma/2469388/In the 2-year pivotal FIREFISH study (NCT02913482) of risdiplam (Evrysdi; Genentech, San Francisco, CA), infants with symptomatic type 1 spinal muscular atrophy (SMA) who were treated with risdiplam at age 2 to 7 months continued to improve and achieve motor milestones. Of the 21 partic
- Virtual Programs and Events Available to Support PD Community Through Ongoing COVID-19 Pandemichttps://practicalneurology.com/news/virtual-programs-and-events-available-to-support-pd-community-through-ongoing-covid-19-pandemic/2469361/The Parkinson's Foundation has continued to host virtual programs and events to support the Parkinson disease (PD) community during the ongoing COVID-19 pandemic. This year, their signature event Fall Moving Day will be online. The Foundation has new events prepared for PD Health@Home, a virt
- Soticlestat Reduces Seizure Frequency in Children with Dravet or Lennox-Gastaut Syndromehttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-children-with-dravet-or-lennox-gastaut-syndrome/2469360/Data from a randomized phase 2 ELEKTRA study (NCT03650452) (Takeda Pharmaceutical, New York, NY) showed soticlestat treatment reduced seizure frequency in children with Dravet syndrome (DS) or Len
- FDA Gives Green Light to Trehelose Phase 2b/3 Trial for ALShttps://practicalneurology.com/news/fda-gives-green-light-to-trehelose-phase-2b3-trial-for-als/2469350/The Food and Drug Administration (FDA) has issued a may proceed notice, allowing the initiation of a phase 2b/3 trial studying trehalose (SLS-005, Seelos Therapeutics, New York, NY) for the treatment of amyotrophic lateral sclerosis (ALS). Familial ALS is caused by mutations in th
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- FDA Approves ppCBD to Treat Seizures Associated with Tuberous Sclerosis Complexhttps://practicalneurology.com/news/fda-approves-ppcbd-to-treat-seizures-associated-with-tuberous-sclerosis-complex/2469341/The Food and Drug Administration (FDA) has approved prescription pharmaceutical cannabidiol (ppCBD) (Epidiolex; GW Pharmaceuticals, Carlsbad, CA) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients age 1 year or more. Along with this new indication, the ag
- FDA Approves New Oxybates Compound for Cataplexy or Excessive Daytime Sleepiness of Narcolepsyhttps://practicalneurology.com/news/fda-approves-new-oxybate-compound-for-cataplexy-or-excessive-daytime-sleepiness-of-narcolepsy/2469330/The Food and Drug Administration (FDA) approved a calcium, magnesium, potassium, and sodium oxybates oral solution (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in individuals age 7 years and more with n